# Ronnie Aronson

List of Publications by Year
in descending order

| 58 papers | 2,776 citations | 257357<br>24 h-index | 182361<br>51 g-index |
|---|---|---|---|
| 58 all docs | 58 docs citations | 58 times ranked | 3120 citing authors |

| # | ARTICLE | IF | CITATIONS |
|---|---------|-----|-----------|
| 1 | Continuous Glucose Monitoring Versus Usual Care in Patients With Type 2 Diabetes Receiving Multiple Daily Insulin Injections. Annals of Internal Medicine, 2017, 167, 365. | 2.0 | 385 |
| 2 | Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by Established Basal Insulin. Diabetes Care, 2013, 36, 2489-2496. | 4.3 | 261 |
| 3 | Serum Urate Lowering with Allopurinol and Kidney Function in Type 1 Diabetes. New England Journal of Medicine, 2020, 382, 2493-2503. | 13.9 | 228 |
| 4 | Rates and predictors of hypoglycaemia in 27 585 people from 24 countries with insulin‐treated type 1 and type 2 diabetes: the global <scp>HAT</scp> study. Diabetes, Obesity and Metabolism, 2016, 18, 907-915. | 2.2 | 203 |
| 5 | Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial. Diabetes Care, 2016, 39, 2026-2035. | 4.3 | 197 |
| 6 | Insulin pump treatment compared with multiple daily injections for treatment of type 2 diabetes (OpT2mise): a randomised open-label controlled trial. Lancet, The, 2014, 384, 1265-1272. | 6.3 | 180 |
| 7 | Efficacy and Safety of Lixisenatide Once-Daily Morning or Evening Injections in Type 2 Diabetes Inadequately Controlled on Metformin (GetGoal-M). Diabetes Care, 2013, 36, 2543-2550. | 4.3 | 150 |
| 8 | Low-Dose Otelixizumab Anti-CD3 Monoclonal Antibody DEFEND-1 Study: Results of the Randomized Phase III Study in Recent-Onset Human Type 1 Diabetes. Diabetes Care, 2014, 37, 2746-2754. | 4.3 | 133 |
| 9 | Long‐term efficacy and safety of ertugliflozin monotherapy in patients with inadequately controlled T2DM despite diet and exercise: VERTIS MONO extension study. Diabetes, Obesity and Metabolism, 2018, 20, 1453-1460. | 2.2 | 70 |
| 10 | The Role of Comfort and Discomfort in Insulin Therapy. Diabetes Technology and Therapeutics, 2012, 14, 741-747. | 2.4 | 62 |
| 11 | Lowest Glucose Variability and Hypoglycemia Are Observed With the Combination of a GLP-1 Receptor Agonist and Basal Insulin (VARIATION Study). Diabetes Care, 2017, 40, 194-200. | 4.3 | 53 |
| 12 | Impact of hypoglycaemia on patient-reported outcomes from a global, 24-country study of 27,585 people with type 1 and insulin-treated type 2 diabetes. Diabetes Research and Clinical Practice, 2017, 130, 121-129. | 1.1 | 53 |
| 13 | Optimal Insulin Correction Factor in Post–High-Intensity Exercise Hyperglycemia in Adults With Type 1 Diabetes: The FIT Study. Diabetes Care, 2019, 42, 10-16. | 4.3 | 53 |
| 14 | Sustained efficacy of insulin pump therapy compared with multiple daily injections in type 2 diabetes: 12‐month data from the <scp>OpT2mise</scp> randomized trial. Diabetes, Obesity and Metabolism, 2016, 18, 500-507. | 2.2 | 52 |
| 15 | Preventing Early Renal Loss in Diabetes (PERL) Study: A Randomized Double-Blinded Trial of Allopurinol–Rationale, Design, and Baseline Data. Diabetes Care, 2019, 42, 1454-1463. | 4.3 | 39 |
| 16 | SGLT2 inhibitors and incretin agents: Associations with alanine aminotransferase activity in type 2 diabetes. Diabetes and Metabolism, 2018, 44, 493-499. | 1.4 | 37 |
| 17 | Dasiglucagon–A Next-Generation Glucagon Analog for Rapid and Effective Treatment of Severe Hypoglycemia: Results of Phase 3 Randomized Double-Blind Clinical Trial. Diabetes Care, 2021, 44, 1361-1367. | 4.3 | 37 |
| 18 | Validation of a type 1 diabetes algorithm using electronic medical records and administrative healthcare data to study the population incidence and prevalence of type 1 diabetes in Ontario, Canada. BMJ Open Diabetes Research and Care, 2020, 8, e001224. | 1.2 | 36 |

| # | Article | IF | Citations |
|---|---------|----|-----------|
| 19 | Insulin Pen Needles: Effects of Extra-Thin Wall Needle Technology on Preference, Confidence, and Other Patient Ratings. Clinical Therapeutics, 2013, 35, 923-933.e4. | 1.1 | 34 |
| 20 | Specialistâ€led diabetes registries and predictors of poor glycemic control in type 2 diabetes: Insights into the functionally refractory patient from the <scp>LMC D</scp>iabetes <scp>R</scp>egistry database. Journal of Diabetes, 2016, 8, 76-85. | 0.8 | 32 |
| 21 | Time Lag and Accuracy of Continuous Glucose Monitoring During High Intensity Interval Training in Adults with Type 1 Diabetes. Diabetes Technology and Therapeutics, 2019, 21, 286-294. | 2.4 | 30 |
| 22 | Semaglutide once weekly in people with type 2 diabetes: Realâ€world analysis of the Canadian <scp>LMC</scp> diabetes registry (<scp>SPARE</scp> study). Diabetes, Obesity and Metabolism, 2020, 22, 2013-2020. | 2.2 | 29 |
| 23 | The Canadian Hypoglycemia Assessment Tool Program: Insights Into Rates and Implications of Hypoglycemia From an Observational Study. Canadian Journal of Diabetes, 2018, 42, 11-17. | 0.4 | 28 |
| 24 | International comparison of glycaemic control in people with type 1 diabetes: an update and extension. Diabetic Medicine, 2022, 39, e14766. | 1.2 | 28 |
| 25 | The Impact of Insulin Pump Therapy on Glycemic Profiles in Patients with Type 2 Diabetes: Data from the OpT2mise Study. Diabetes Technology and Therapeutics, 2016, 18, 22-28. | 2.4 | 27 |
| 26 | First assessment of the performance of an implantable continuous glucose monitoring system through 180 days in a primarily adolescent population with type 1 diabetes. Diabetes, Obesity and Metabolism, 2019, 21, 1689-1694. | 2.2 | 27 |
| 27 | Reproducibility in the cardiometabolic responses to high-intensity interval exercise in adults with type 1 diabetes. Diabetes Research and Clinical Practice, 2019, 148, 137-143. | 1.1 | 24 |
| 28 | OpT2mise: A Randomized Controlled Trial to Compare Insulin Pump Therapy with Multiple Daily Injections in the Treatment of Type 2 Diabetesâ€"Research Design and Methods. Diabetes Technology and Therapeutics, 2014, 16, 414-420. | 2.4 | 21 |
| 29 | Specialist-Led Diabetes Registries and Prevalence of Poor Glycemic Control in Type 2 Diabetes: The Diabetes Registry Outcomes Project for A1C Reduction (DROP A1C). Diabetes Care, 2016, 39, 1711-1717. | 4.3 | 21 |
| 30 | Effect of Dapagliflozin on Glycemic Control, Weight, and Blood Pressure in Patients with Type 2 Diabetes Attending a Specialist Endocrinology Practice in Canada: A Retrospective Cohort Analysis. Diabetes Technology and Therapeutics, 2017, 19, 685-691. | 2.4 | 20 |
| 31 | Direct and indirect health economic impact of hypoglycaemia in a global population of patients with insulin-treated diabetes. Diabetes Research and Clinical Practice, 2018, 138, 35-43. | 1.1 | 19 |
| 32 | Screening and Treatment Outcomes in Adults and Children With Type 1 Diabetes and Asymptomatic Celiac Disease: The CD-DIET Study. Diabetes Care, 2020, 43, 1553-1556. | 4.3 | 19 |
| 33 | The Canadian LMC Diabetes Registry: A Profile of the Demographics, Management, and Outcomes of Individuals with Type 1 Diabetes. Diabetes Technology and Therapeutics, 2021, 23, 31-40. | 2.4 | 18 |
| 34 | Insulin glargine/lixisenatide fixedâ€ratio combination improves glycaemic variability and control without increasing hypoglycaemia. Diabetes, Obesity and Metabolism, 2019, 21, 726-731. | 2.2 | 16 |
| 35 | Comparison of the HAT study, the largest global hypoglycaemia study to date, with similar large realâ€world studies. Diabetes, Obesity and Metabolism, 2019, 21, 844-853. | 2.2 | 15 |
| 36 | Real-World Health Outcomes of Insulin Glargine 300 U/mL vs Insulin Glargine 100 U/mL in Adults With Type 1 and Type 2 Diabetes in the Canadian LMC Diabetes Patient Registry: The REALITY Study. Canadian Journal of Diabetes, 2019, 43, 504-509.e1. | 0.4 | 14 |

| # | Article | IF | Citations |
|---|---------|----|-----------|
| 37 | Flexible insulin therapy with a hybrid regimen of insulin degludec and continuous subcutaneous insulin infusion with pump suspension before exercise in physically active adults with type 1 diabetes (FIT Untethered): a single-centre, open-label, proof-of-concept, randomised crossover trial. Lancet Diabetes and Endocrinology,the, 2020, 8, 511-523. | 5.5 | 13 |
| 38 | Single-pill combination therapy for type 2 diabetes mellitus: linagliptin plus empagliflozin. Current Medical Research and Opinion, 2015, 31, 901-911. | 0.9 | 11 |
| 39 | The Need Associated with Diabetes Primary Care and the Impact of Referral to a Specialist-Centered Multidisciplinary Diabetes Program (the NADIR Study). Canadian Journal of Diabetes, 2016, 40, 120-125. | 0.4 | 10 |
| 40 | Paradoxical Rise in Hypoglycemia Symptoms With Development of Hyperglycemia During High-Intensity Interval Training in Type 1 Diabetes. Diabetes Care, 2019, 42, 2011-2014. | 4.3 | 10 |
| 41 | The LMC Skills, Confidence & Preparedness Index (SCPI): development and evaluation of a novel tool for assessing self-management in patients with diabetes. Health and Quality of Life Outcomes, 2017, 15, 27. | 1.0 | 9 |
| 42 | Factors associated with improved glycemic control following continuous subcutaneous insulin infusion therapy in patients with type 2 diabetes uncontrolled with bolus–basal insulin regimens: <scp>A</scp>n analysis from the <scp>OpT2mise</scp> randomized trial. Diabetes, Obesity and Metabolism, 2017, 19, 1490-1494. | 2.2 | 8 |
| 43 | Patient Reported Outcomes following initiation of Glucagon-like peptide-1 Receptor agonists in patients with type 2 Diabetes in a specialist endocrinology practice of the LMC diabetes registry: The PROGRESS-Diabetes study. Diabetes Research and Clinical Practice, 2019, 156, 107820. | 1.1 | 8 |
| 44 | Assessment of self-management in patients with diabetes using the novel LMC Skills, Confidence and Preparedness Index (SCPI). Diabetes Research and Clinical Practice, 2018, 137, 128-136. | 1.1 | 7 |
| 45 | Impact of a Gluten-Free Diet on Quality of Life and Health Perception in Patients With Type 1 Diabetes and Asymptomatic Celiac Disease. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e1984-e1992. | 1.8 | 7 |
| 46 | Prevalence and Risk Evaluation of Diabetic Complications of the Foot Among Adults With Type 1 and Type 2 Diabetes in a Large Canadian Population (PEDAL Study). Canadian Journal of Diabetes, 2021, 45, 588-593. | 0.4 | 6 |
| 47 | Goal achievement of <scp>HbA1c</scp> and <scp>LDL‐</scp>cholesterol in a randomized trial comparing colesevelam with ezetimibe: <scp>GOAL‐RCT</scp>. Diabetes, Obesity and Metabolism, 2020, 22, 1722-1728. | 2.2 | 6 |
| 48 | Optimizing Diabetes Self-management Using the Novel Skills, Confidence, and Preparedness Index (SCPI). Diabetes Care, 2019, 42, 1873-1878. | 4.3 | 5 |
| 49 | Efficacy, safety, tolerability, and noninferiority phase 3 study of glucagon as a ready‐to‐use room temperature liquid stable formulation versus a lyophilised formulation for the biochemical recovery and symptomatic relief of insulin‐induced severe hypoglycaemia in adults with type 1 diabetes. Diabetes, Obesity and Metabolism, 2022, 24, 1394-1397. | 2.2 | 5 |
| 50 | Optimizing glycemic control: lixisenatide and basal insulin in combination therapy for the treatment of Type 2 diabetes mellitus. Expert Review of Clinical Pharmacology, 2013, 6, 603-612. | 1.3 | 4 |
| 51 | Factors affecting the benefit of insulin dose intensification in people with Type 2 diabetes: an analysis from the OpT2mise randomized trial. Diabetic Medicine, 2017, 34, 291-292. | 1.2 | 4 |
| 52 | Canadian Real‐World Outcomes of Omnipod Initiation in People with Type 1 Diabetes (COPPER study): Evidence from the LMC Diabetes Registry. Diabetic Medicine, 2021, 38, e14420. | 1.2 | 4 |
| 53 | Reliability and validity of the Chinese version of the LMC Skills, Confidence &amp; Preparedness Index (SCPI) in patients with type 2 diabetes. Health and Quality of Life Outcomes, 2021, 19, 25. | 1.0 | 3 |
| 54 | Combination therapy in type 2 diabetes mellitus: adding linagliptin to a stable regimen of metformin and a sulfonylurea. Expert Opinion on Pharmacotherapy, 2012, 13, 1535-1539. | 0.9 | 2 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 55 | The Need Associated with Diabetes Primary Care and the Impact of Referral to a Specialist-centered Multi-disciplinary Diabetes Program (NADIR study). Canadian Journal of Diabetes, 2012, 36, S40. | 0.4 | 1 |
| 56 | Advanced Self-Care Program: Preliminary Results from a 6-Month Intervention for Patients with Chronically Uncontrolled Diabetes. Canadian Journal of Diabetes, 2017, 41, S23. | 0.4 | 1 |
| 57 | Optimal Insulin Correction Factor (ICF) for Post-exercise Hyperglycemia following High-Intensity Training in Adults with Type 1 Diabetes (T1D)â€"The FIT Study. Diabetes, 2018, 67, 732-P. | 0.3 | 1 |
| 58 | Safety and Effectiveness of an Investigational Insulin Delivery Device Providing Basal/Bolus Therapy with Rapid-Acting or Regular Human Insulin in Adults with Type 2 Diabetes. Diabetes Technology and Therapeutics, 2020, 22, 352-359. | 2.4 | 0 |